WHO’s 2026 Smart Pharmacovigilance Resolution: What WHA79.11 Means for Marketing Authorisation Holders

In May 2026, the 79th World Health Assembly adopted Resolution WHA79.11 on smart and efficient pharmacovigilance. The resolution places medicine, vaccine and health-technology safety monitoring at the centre of resilient health systems and calls for stronger regulatory capacity, skilled workforces, digital tools, real-world data and timely risk communication.

For marketing authorisation holders (MAHs), especially those operating across CIS and EAEU markets, this is more than a policy statement. It signals the direction in which national pharmacovigilance expectations are likely to develop: better integrated safety data, faster signal detection, documented governance and clearer communication with patients and healthcare professionals.

What is smart pharmacovigilance?

Smart pharmacovigilance combines established drug-safety processes with proportionate digitalisation, reliable real-world evidence and risk-based decision-making. Technology does not replace qualified medical judgement. It helps pharmacovigilance teams identify patterns earlier, prioritise cases consistently and make safety information available to regulators and stakeholders at the right time.

• integrated reporting of adverse drug reactions and adverse events;
• structured signal detection and signal management;
• use of real-world data and digital safety-surveillance tools;
• strong data quality, privacy, validation and audit trails;
• effective benefit-risk assessment and risk minimisation;
• timely, evidence-based safety communication.

Why WHA79.11 matters for MAHs

The WHO resolution encourages Member States to integrate pharmacovigilance into health systems and strengthen regulatory capability. As national authorities translate these principles into local programmes, MAHs should expect increasing attention to the completeness, traceability and interoperability of safety information.

1. Faster and more defensible signal management

Signal detection must be supported by documented methods, defined responsibilities and clear escalation routes. Automated screening or artificial intelligence may support prioritisation, but outputs require validation, human oversight and a reproducible audit trail.

2. Greater use of real-world data

Spontaneous reports remain essential, yet electronic health records, registries, scientific literature, patient programmes and other real-world sources can add context to emerging risks. MAHs need procedures that define data fitness, limitations, privacy safeguards and how evidence contributes to benefit-risk decisions.

3. Stronger local and global coordination

Companies working in multiple jurisdictions need reliable communication between the global safety function, QPPV, local contact persons, affiliates, distributors and partners. Safety Data Exchange Agreements should define timelines, case ownership, reconciliation, signal exchange and regulatory responsibilities.

4. Risk communication as a core safety activity

WHA79.11 highlights timely risk communication and the need to counter misinformation. MAHs should therefore connect signal management, risk-minimisation measures, medical information and public communication. Messages must be accurate, understandable, locally appropriate and aligned with regulatory decisions.

A practical readiness checklist for 2026

1. Review the pharmacovigilance system master file and local system descriptions.
2. Map all safety-data sources, owners, transfer routes and reconciliation controls.
3. Assess signal-detection procedures, validation criteria and governance.
4. Verify oversight of vendors, partners and local contact persons.
5. Confirm that digital tools are validated and supported by access controls and audit trails.
6. Evaluate whether real-world data are used with clear quality and privacy standards.
7. Test escalation and safety-communication workflows through training or simulation.
8. Update training plans for pharmacovigilance, medical, regulatory and commercial teams.
9. Track WHO, EAEU and national regulatory developments through regulatory intelligence.

Implications for CIS and EAEU markets

Implementation will differ by country, but the strategic direction is consistent: pharmacovigilance systems should be connected, capable of learning and able to act rapidly on credible safety information. Regional MAHs should avoid a one-size-fits-all approach. Global standards must be translated into country-specific procedures, reporting timelines and local contact arrangements.

PharmExpert supports marketing authorisation holders with QPPV and local contact person services, pharmacovigilance system master files, literature and regulatory monitoring, adverse-event case management, signal management, aggregate reports, risk-management plans, audits, training and end-to-end pharmacovigilance outsourcing across CIS and EAEU markets.

Conclusion

WHA79.11 makes smart pharmacovigilance a global health-system priority. The most effective response for MAHs is not technology adoption in isolation, but a controlled operating model that combines high-quality data, competent people, validated tools, local regulatory expertise and transparent benefit-risk decisions.

Need to assess your pharmacovigilance readiness for 2026? Contact PharmExpert for a tailored gap assessment and implementation plan for CIS and EAEU markets.

---

Source: World Health Organization, Resolution WHA79.11, adopted by the 79th World Health Assembly on 24 May 2026. This article is for general informational purposes and does not constitute legal or regulatory advice.